Clinical aspects of the different forms of viral hepatitis and their treatment

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue SUPPL. 1, 2002, Pages 37-46

  Goeser, Tobias ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; RIBAVIRIN; URSODEOXYCHOLIC ACID;

CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DELTA AGENT HEPATITIS; DISEASE COURSE; DRUG INDICATION; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HEPATITIS G VIRUS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036236422     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-30194     Document Type: Conference Paper

References (57)

1. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease
2. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
3. Long-term remission of chronic hepatitis B after alpha-interferon therapy
4. Survival in chronic hepatitis B. An analysis of 379 patients
5. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
6. The HBe antigen-antibody system and its relationship to clinical and laboratory findings in 100 chronic HBsAg carriers in Great Britain
7. Hepatocellular carcinoma in Italian patients with cirrhosis
8. Long-term follow-up of HbeAg-positive patients treated with interferon alpha for chronic hepatitis B
9. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy
10. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha
11. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
12. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors
13. Behandlung der chronischen hepatitis B mit interferon alpha-2b
14. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
15. Effect of alpha-interferon treatment in patients with HBe-Ag-positive chronic hepatitis B. A meta-analysis
16. Prospective, randomized, controlled trial of interferon-alpha in children with chronic hepatitis B
17. Effectiveness and tolerability of prolonged interferon treatment in patients with HbsAg-positive chronic hepatitis
18. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine
19. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alpha
20. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years
21. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus
22. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
23. Extended lamivudine retreatment for chronic hepatitis B
24. Liver transplantation in European patients with the hepatitis B surface antigen
25. Treatment of chronic hepatitis D with interferon alpha-2a
26. Natural history of liver fibrosis progression in patients with chronic hepatitis C
27. Hepatitis C virus, alcoholic cirrhosis, and hepatocellular carcinoma
28. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses
29. Interferon-alpha in acute posttransfusion hepatitis C: A randomized, controlled trial
30. A multicenter randomized controlled trial of recombinant interferon-alpha-2b in patients with acute transfusion-associated hepatitis C
31. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled dose study
32. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter, randomized, controlled trial
33. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
34. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C
35. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
36. Factors predictive of the response to interferon in patients with chronic hepatitis C
37. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
38. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alpha-2a as therapy for chronic hepatitis C
39. Bedeutung der genotypen bei chronischer hepatitis C virusinfektion und hepatitis C- bedingter leberzirrhose
40. Response to interferon is influenced by the iron content of the liver
41. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon
42. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis
43. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity
44. Recombinant interferon-alpha therapy in children with chronic hepatitis C
45. Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus
46. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
47. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients
48. Alpha-interferon retreatment of patients with chronic hepatitis C
49. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
50. Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
51. Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial
52. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients
53. Recurrent hepatitis C virus infection after liver transplantation
54. Liver transplantation for hepatitis C virus-related cirrhosis
55. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
56. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin
57. Clinical presentation of GB-C virus in drug abusers with chronic hepatitis C